Fate Financial Statements From 2010 to 2025

FATE Stock  USD 0.92  0.05  5.15%   
Fate Therapeutics financial statements provide useful quarterly and yearly information to potential Fate Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Fate Therapeutics financial statements helps investors assess Fate Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Fate Therapeutics' valuation are summarized below:
Gross Profit
-104.9 M
Market Capitalization
110.7 M
Enterprise Value Revenue
20.3944
Revenue
13.6 M
Earnings Share
(1.64)
There are over one hundred nineteen available fundamental signals for Fate Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to verify all of Fate Therapeutics' prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. As of March 19, 2025, Market Cap is expected to decline to about 178.2 M. In addition to that, Enterprise Value is expected to decline to about 225 M

Fate Therapeutics Total Revenue

22.94 Million

Check Fate Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fate Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 19.9 M, Interest Expense of 7.1 M or Selling General Administrative of 77.9 M, as well as many indicators such as Price To Sales Ratio of 13.07, Dividend Yield of 0.0 or PTB Ratio of 0.56. Fate financial statements analysis is a perfect complement when working with Fate Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Fate Therapeutics Correlation against competitors.
For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.

Fate Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets322.6 M440.7 M277.3 M
Slightly volatile
Short and Long Term Debt Total49.7 M85.3 M43 M
Slightly volatile
Other Current Liabilities18.1 M21.3 M15.5 M
Slightly volatile
Total Current Liabilities37 M38.5 M32 M
Slightly volatile
Other Liabilities4.2 M4.4 M10 M
Slightly volatile
Property Plant And Equipment Net116.4 M110.9 M39.3 M
Slightly volatile
Current Deferred Revenue373.4 K393 K6.7 M
Slightly volatile
Accounts Payable9.8 M9.4 M4.3 M
Slightly volatile
Cash34.3 M36.1 M70.8 M
Slightly volatile
Non Current Assets Total81.5 M148.8 M70 M
Slightly volatile
Non Currrent Assets Other9.7 M10.2 M20.8 M
Slightly volatile
Other Assets1.091.159.3 M
Pretty Stable
Cash And Short Term Investments230.1 M279.1 M197.8 M
Slightly volatile
Common Stock Total Equity115.9 K110.4 K56.9 K
Slightly volatile
Common Stock Shares Outstanding59.2 M113.7 M51.4 M
Slightly volatile
Liabilities And Stockholders Equity322.6 M440.7 M277.3 M
Slightly volatile
Non Current Liabilities Total65.3 M83.4 M59.5 M
Slightly volatile
Other Current Assets6.2 M9.3 M5.3 M
Slightly volatile
Total Liabilities102.3 M122 M91.4 M
Slightly volatile
Property Plant And Equipment Gross153.3 M146 M49.5 M
Slightly volatile
Total Current Assets241.1 M291.9 M207.2 M
Slightly volatile
Short Term DebtM7.4 M5.2 M
Slightly volatile
Common Stock62.9 K114 K54.1 K
Slightly volatile
Property Plant Equipment212.6 M202.5 M61.9 M
Slightly volatile
Net Tangible Assets584.4 M556.5 M261.8 M
Slightly volatile
Capital Surpluse1.7 B1.7 B699.5 M
Slightly volatile
Deferred Long Term LiabilitiesM8.3 M4.1 M
Slightly volatile
Long Term Debt Total9.4 M11.2 M13.4 M
Slightly volatile
Short and Long Term Debt2.7 M2.8 M3.6 M
Very volatile
Non Current Liabilities Other6.1 M5.8 M1.7 M
Slightly volatile
Net Invested Capital377.6 M318.7 M235.5 M
Slightly volatile
Net Working Capital325 M253.4 M208.1 M
Slightly volatile
Net Receivables3.4 M3.5 M4.2 M
Slightly volatile
Capital Stock103.1 K117 K81.4 K
Slightly volatile
Capital Lease Obligations98.5 M85.3 M54.9 M
Slightly volatile

Fate Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization19.9 M19 M5.7 M
Slightly volatile
Interest Expense7.1 M6.7 M2.7 M
Slightly volatile
Selling General Administrative77.9 M74.2 M31.7 M
Slightly volatile
Other Operating Expenses132.4 M223.9 M114.5 M
Slightly volatile
Research Development97.7 M135 M84.5 M
Slightly volatile
Cost Of Revenue195.2 M186 M62.4 M
Slightly volatile
Total Operating Expenses132.4 M223.9 M114.5 M
Slightly volatile
Interest Income18.2 M17.3 M5.1 M
Slightly volatile
Reconciled Depreciation19.9 M19 M5.7 M
Slightly volatile
Selling And Marketing Expenses1.6 M1.8 MM
Slightly volatile

Fate Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation22.5 M41.5 M19.3 M
Slightly volatile
Begin Period Cash Flow88.6 M57 M76.8 M
Slightly volatile
Other Cashflows From Financing Activities27.5 M25.4 M24.1 M
Very volatile
Depreciation10.4 M9.9 M4.4 M
Slightly volatile
Capital Expenditures693.5 K730 K7.1 M
Slightly volatile
Total Cash From Financing Activities108.4 M99.9 M93.4 M
Slightly volatile
End Period Cash Flow91.4 M46.3 M78.8 M
Slightly volatile
Change To Netincome62.5 M59.6 M21.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio13.0713.761366.0428
Very volatile
Days Sales Outstanding54.7194.764552.3196
Slightly volatile
Stock Based Compensation To Revenue3.23.04421.1365
Slightly volatile
Capex To Depreciation0.07020.07391.6565
Pretty Stable
EV To Sales16.517.371455.3837
Very volatile
Days Of Inventory On Hand0.00.00.0
Slightly volatile
Payables Turnover41.3739.419.1818
Slightly volatile
Sales General And Administrative To Revenue3.125.44123.0183
Slightly volatile
Average Inventory0.40.450.4906
Slightly volatile
Research And Ddevelopement To Revenue7.769.9047.2518
Slightly volatile
Capex To Revenue0.05090.05360.3181
Very volatile
Cash Per Share2.522.45472.9602
Slightly volatile
Days Payables Outstanding9.119.5965.7472
Pretty Stable
Income Quality0.840.65970.7707
Pretty Stable
Current Ratio5.527.57776.4991
Slightly volatile
Receivables Turnover3.663.85179.2478
Very volatile
Capex Per Share0.00610.00640.0898
Slightly volatile
Revenue Per Share0.230.11990.2653
Slightly volatile
Interest Debt Per Share0.560.750.6837
Slightly volatile
Debt To Assets0.230.19350.2327
Slightly volatile
Operating Cycle54.7194.764552.3196
Slightly volatile
Days Of Payables Outstanding9.119.5965.7472
Pretty Stable
Ebt Per Ebit1.130.88581.0319
Pretty Stable
Quick Ratio5.527.57776.4991
Slightly volatile
Net Income Per E B T1.061.040.9888
Very volatile
Cash Ratio0.890.9364.0083
Slightly volatile
Days Of Inventory Outstanding0.00.00.0
Slightly volatile
Days Of Sales Outstanding54.7194.764552.3196
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.861.00591.0559
Pretty Stable
Fixed Asset Turnover0.120.12291.0717
Slightly volatile
Debt Ratio0.230.19350.2327
Slightly volatile
Price Sales Ratio13.0713.761366.0428
Very volatile
Asset Turnover0.02940.03090.0753
Slightly volatile

Fate Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap178.2 M187.6 M1.1 B
Slightly volatile
Enterprise Value225 M236.8 M1.1 B
Slightly volatile

Fate Fundamental Market Drivers

Cash And Short Term Investments279.1 M

Fate Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Fate Therapeutics Financial Statements

Fate Therapeutics stakeholders use historical fundamental indicators, such as Fate Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Fate Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Fate Therapeutics' assets and liabilities are reflected in the revenues and expenses on Fate Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Fate Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue393 K373.4 K
Total Revenue13.6 M22.9 M
Cost Of Revenue186 M195.2 M
Stock Based Compensation To Revenue 3.04  3.20 
Sales General And Administrative To Revenue 5.44  3.12 
Research And Ddevelopement To Revenue 9.90  7.76 
Capex To Revenue 0.05  0.05 
Revenue Per Share 0.12  0.23 
Ebit Per Revenue(15.43)(14.65)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Fate Therapeutics is a strong investment it is important to analyze Fate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Fate Therapeutics' future performance. For an informed investment choice regarding Fate Stock, refer to the following important reports:
Check out the analysis of Fate Therapeutics Correlation against competitors.
For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.64)
Revenue Per Share
0.12
Quarterly Revenue Growth
0.11
Return On Assets
(0.26)
Return On Equity
(0.54)
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.